On Jul. 14, 2020, Dynavax Technologies announced that the first participants have been dosed in the Phase 1 clinical trial evaluating Medicagoﾒs plant-derived vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19.

The previously announced collaboration began evaluating the combination of Medicagoﾒs Coronavirus Virus-Like Particle with Dynavaxﾒs CpG 1018, the adjuvant in Dynavaxﾒs FDA-approved adult hepatitis B vaccine.